NCT05527808View on ClinicalTrials.gov

A Single-arm Exploratory Study of Neoadjuvant Therapy

NARecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions
Lung Adenocarcinoma
Interventions
DRUG

Tislelizumab

200 mg ,intravenous injection ,Q3W 2-4 cycles

DRUG

pemetrexed

500 mg/m2,intravenous injection ,Q3W 2-4 cycles

DRUG

cis-platemum

60-75mg/m2 ,intravenous injection ,Q3W 2-4 cycles

DRUG

or carboplatin

AUC(4-5) ,intravenous injection ,Q3W 2-4 cycles

Trial Locations (1)

510000

RECRUITING

First Affiliated Hospital, Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Jun Liu

OTHER